

Cite this article as: Benedetto U, Altman DG, Gerry S, Gray A, Lees B, Flather M *et al.* Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial. *Eur J Cardiothorac Surg* 2017;52:456–61.

Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial†

Umberto Benedetto^{a,*}, Douglas G. Altman^b, Stephen Gerry^b, Alastair Gray^c, Belinda Lees^d, Marcus Flather^e and David P. Taggart^d, on behalf of the ART Investigators

^a Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK

^b Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford, UK

^c Department of Public Health, Health Economics Research Centre, University of Oxford, Headington, Oxford, UK

^d Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK

^e Research and Development Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK

* Corresponding author. Bristol Heart Institute, University of Bristol, Senate House, Tyndall Avenue, Bristol BS8 1TH, UK. Tel: +44-117-9289000; e-mail: umberto.benedetto@hotmail.com (U. Benedetto).

Received 10 November 2016; received in revised form 25 January 2017; accepted 12 February 2017

Abstract

OBJECTIVES: There is still little evidence to support routine dual antiplatelet therapy (DAPT) with P₂Y₁₂ antagonists following coronary artery bypass grafting (CABG). The Arterial Revascularization Trial (ART) was designed to compare 10-year survival after bilateral versus single internal thoracic artery grafting. We aimed to get insights into the effect of DAPT (with clopidogrel) following CABG on 1-year outcomes by performing a *post hoc* ART analysis.

METHODS: Among patients enrolled in the ART ($n = 3102$), 609 (21%) and 2308 (79%) were discharged on DAPT or aspirin alone, respectively. The primary end-point was the incidence of major adverse cerebrovascular and cardiac events (MACCE) at 1 year including cardiac death, myocardial infarction, cerebrovascular accident and reintervention; safety end-point was bleeding requiring hospitalization. Propensity score (PS) matching was used to create comparable groups.

RESULTS: Among 609 PS-matched pairs, MACCE occurred in 34 (5.6%) and 34 (5.6%) in the DAPT and aspirin alone groups, respectively, with no significant difference between the 2 groups [hazard ratio (HR) 0.97, 95% confidence interval (CI) 0.59–1.59; $P = 0.90$]. Only 188 (31%) subjects completed 1 year of DAPT, and in this subgroup, MACCE rate was 5.8% (HR 1.11, 95% CI 0.53–2.30; $P = 0.78$). In the overall sample, bleeding rate was higher in DAPT group (2.3% vs 1.1%; $P = 0.02$), although this difference was no longer significant after matching (2.3% vs 1.8%; $P = 0.54$).

CONCLUSIONS: Based on these findings, when compared with aspirin alone, DAPT with clopidogrel prescribed at discharge was not associated with a significant reduction of adverse cardiac and cerebrovascular events at 1 year following CABG.

Keywords: Dual antiplatelet therapy • Coronary artery bypass grafting • Bleeding

INTRODUCTION

Coronary artery bypass grafting (CABG) is widely regarded as the revascularization strategy of choice, particularly in patients with multivessel coronary artery disease [1]. However, CABG patients still have a significant risk of subsequent major adverse cardiovascular events [major adverse cerebrovascular and cardiac events (MACCE), including mortality, myocardial infarction (MI), stroke and repeat revascularization] secondary to graft failure and atherosclerosis progression, particularly during the first 12 months. In fact, MACCE rates in the first year after CABG still exceed 12% [2].

The appropriate antiplatelet regimen after CABG remains an area of controversy [3]. Dual antiplatelet therapy (DAPT) with the addition of an oral P₂Y₁₂ antagonist such as clopidogrel to aspirin for 1 year after surgery has been proposed to improve outcomes. Plaque stability, prevention of graft closure and secondary thrombosis form the basis for using a second antiplatelet drug, whereas the increased risk of bleeding and lack of conclusive evidence should also be considered.

Evidence for use of DAPT following CABG [4] is based mainly on a small proportion of patients undergoing surgical revascularization in landmark trials enrolling acute coronary syndrome (ACS) patients [5–7]. Whereas cardiac surgeons are very familiar with the guidelines regarding discontinuation of DAPT prior to CABG to minimize bleeding risks [8, 9], there is

†Presented at the 30th Annual Meeting of the European Association for Cardio-Thoracic Surgery, Barcelona, Spain, 1–5 October 2016.

considerable variability in DAPT resumption in post-CABG [10, 11].

The Arterial Revascularization Trial (ART) was designed to investigate whether bilateral internal thoracic artery grafting is associated with improved 10-year survival when compared with single internal thoracic artery grafting in patients with multivessel disease undergoing CABG [12] and final results will be available in 2018. We aimed to get insights into the efficacy and safety of DAPT following CABG on 1-year outcomes by performing a retrospective analysis of the ART trial.

MATERIALS AND METHODS

This research adheres to the principles set forth in the Declaration of Helsinki (<http://www.wma.net/en/30publications/10policies/b3/index.html>). For the purpose of the present analysis, patients enrolled in the ART ($n = 3102$) were classified according to whether they were discharged on DAPT (with clopidogrel) or aspirin alone following surgery. In the ART, antiplatelet therapy prescribed at discharge was at discretion of responsible physicians. We excluded those who met the following criteria: (i) hospital death, (ii) withdrawn, (iii) no information on antiplatelet therapy at discharge and (iv) clopidogrel alone at discharge.

Trial design

The protocol for the ART has been published [13]. Briefly, the ART is a 2-arm, randomized multicentre trial conducted in 28 hospitals in 7 countries, with patients being randomized equally to single internal thoracic artery or bilateral internal thoracic artery grafts. Eligible patients were those with multivessel coronary artery disease undergoing CABG including urgent patients. Emergency patients (ongoing myocardial ischaemia/cardiogenic shock) and those requiring single grafts or redo CABG were excluded.

Follow-up and study end-points

Questionnaires were sent to study participants by post at 1 year after surgery. No clinic visits were planned apart from the routine clinical 6-week postoperative visit. Participants were sent stamped addressed envelopes to improve the return rates of postal questionnaires. Study coordinators contacted participants by telephone to alert them to the questionnaire's arrival and to ask them about medications, adverse events and health services resource use.

The primary end-point was the incidence of MACCE at 1 year defined as the occurrence of cardiovascular (CV) death, MI, either ST elevation or non-ST elevation MI, cerebrovascular accident (CVA) or repeat revascularization. We also investigated the composite end-point of cardiac death, MI and CVA and all-cause mortality. Safety end-point was bleeding requiring rehospitalization. Adverse events were adjudicated blind to surgical procedure by a member of the Clinical Event Review Committee. Follow-up at 1 year was available for all patients included in the analysis (100%).

Statistical analysis

Multiple imputation was used to address missing data (<http://www.jstatsoft.org/v45/i07/>). Expectation-maximization with bootstrapping algorithm was used to generate 3 imputed data sets. No prior information was used. Sets of estimates from different data sets were combined using the Rubin rule: the central estimate corresponds to the mean of individual imputation estimates and the variance is the weighted sum of 2 variances: the within imputation variance and the between imputation variance [14]. Due to lack of randomization with regard to DAPT administration following surgery, a propensity score (PS) was generated for each patient from a multivariable logistic regression model based on pretreatment covariates as independent variables with DAPT versus aspirin alone administration as a binary dependent variable [15]. Covariates included in the PS model were age, female gender, body mass index, creatinine, diabetes mellitus, smoking, chronic obstructive pulmonary disease, peripheral vascular disease, left ventricular ejection fraction, left main disease, MI (including both ST elevation and non-ST elevation MI), percutaneous coronary intervention, unstable angina (UA), off-pump CABG, use of saphenous vein graft (SVG) and other medication prescribed at discharge, such as vitamin K antagonist, beta blockers, angiotensin converting enzyme inhibitor and angiotensin receptor blocker.

Pairs of patients were derived using greedy 1:1 matching with a caliper of width of 0.2 SD of the logit of the PS (<http://CRAN.Rproject.org/package=nonrandom>). The quality of the match was assessed by comparing selected pretreatment variables in PS-matched patients using the standardized mean difference, for which an absolute standardized difference >10% is suggested to represent meaningful covariate imbalance [16]. A Cox regression model, stratified on the matched pairs [14] and adjusted for other medications at discharge, was used to estimate the treatment effect (i.e. DAPT vs aspirin alone) on outcomes of interest (<http://CRAN.R-project.org/package=survival>). This approach accounts for the within-pair homogeneity by allowing the baseline hazard function to vary across matched sets. For competing risk adverse event (MI, CVA and repeat revascularization), a competing risk framework was used (<https://CRAN.R-project.org/package=riskRegression>). Potential effect modifiers (interaction terms) examined were as follows: (i) UA, (ii) prior MI within 1 year, (iii) prior percutaneous coronary intervention within 1 year, (iv) off-pump surgery and (v) use of SVG. Double robust method (multivariate adjustment in the PS-matched sample) was used to compute treatment effect estimates within subgroups. The proportional hazard assumption was tested by graphical inspection using $\log(-\log(S))$ method with Kaplan–Meier estimators from the PS-matched sample. In this case, the space between the 2 curves should be constant over time (Supplementary Material, Fig. S1, for the primary end-point). A goodness-of-fit test (Schoenfeld residuals) was used to confirm that residuals for the treatment variable were not related to time ($P = 0.49$ for the primary end-point). A generic binomial test was used for a *post hoc* power calculation for the primary end-point. Time-to-event analysis was graphically presented as cumulative incidence curves that show the cumulative probabilities of experiencing the event of interest. Cumulative incidence was computed as $1 - S_t$, where S_t corresponds to the proportion surviving past interval t , obtained from the life table using the Kaplan–Meier approach. All P -values <0.05 were considered to indicate statistical significance. All statistical analyses were performed using R Statistical Software (version 3.2.3; R Foundation for Statistical Computing, Vienna, Austria).




Figure 1: Standardized mean difference (SMD) for baseline variables before and after PS matching. DAPT: dual antiplatelet therapy; PS: propensity score; BMI: body mass index; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; UA: unstable angina; LVEF: left ventricular ejection fraction; AF: atrial fibrillation; SVG: saphenous vein graft; OPCAB: off-pump coronary artery bypass; VKA: vitamin K antagonist; BB: beta blocker; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.

RESULTS

The final study population consisted of 2917 patients. Of them, 609 (21%) and 2308 (79%) were discharged on DAPT or aspirin alone, respectively. Baseline characteristics of the 2 groups are presented in Table 1. In particular, patients receiving DAPT were more likely to have UA and to receive clopidogrel preoperatively. Patients discharged on DAPT were more likely to have off-pump surgery, to receive SVG and to be discharged on statins and angiotensin converting enzyme inhibitor/angiotensin receptor blocker. The use of vitamin K antagonists at discharge was higher in the aspirin group (Fig. 1). After PS matching, the 2 groups were comparable for all pretreatment variables investigated (Fig. 1).

Efficacy end-points

Efficacy end-points in the 609 PS-matched pairs are presented in Table 2. The rate of MACCE was 34 (5.6%) and 34 (5.6%) in the DAPT and aspirin alone groups, respectively, with no significant difference between the 2 groups [hazard ratio (HR) 0.97, 95% confidence interval (CI) 0.59–1.59; $P=0.90$; Fig. 2A]. The rate of the composite of CV death, MI and stroke was 21 (3.5%) and 29

(4.8%) in the DAPT and aspirin alone groups (HR 0.71, 95% CI 0.40–1.27; $P=0.20$; Fig. 2B).

None of the possible effect modifiers showed a significant interaction with MACCE: UA ($\beta = -0.39 \pm 0.70$; $P=0.57$); prior MI ($\beta = 0.1 \pm 0.87$; $P=0.98$) or prior percutaneous coronary intervention within 1 year ($\beta = -0.04 \pm 1.55$; $P=0.97$), off-pump CABG ($\beta = -0.82 \pm 0.69$; $P=0.23$) and use of SVGs ($\beta = -0.35 \pm 0.97$; $P=0.71$). However, UA, off-pump CABG and the use of SVG showed larger coefficients in favour of a benefit from DAPT. In particular, in patients with UA, DAPT did not significantly influence the risk of MACCE (HR_{DR} 0.90, 95% CI 0.40–2.06; $P=0.81$) but was associated with a lower risk for the composite of CV death, MI and CVA (HR_{DR} 0.42, 95% CI 0.15–1.21; $P=0.1$). In patients undergoing off-pump surgery, DAPT did not significantly influence the risk of MACCE (HR_{DR} 0.90, 95% CI 0.50–1.63; $P=0.73$) but was associated with a lower risk for the composite of CV death, MI and CVA (HR_{DR} 0.53, 95% CI 0.25–1.11; $P=0.09$).

Among 609 patients who received DAPT postoperatively, 188 (31%) completed 1 year of DAPT, 362 (59%) switched to aspirin alone and other 24 (4%) switched to clopidogrel alone (unknown for the remaining 35 patients). The rate of MACCE and the composite of CV death, MI and CVA was 5.8% and 2.7%, respectively, for those who continued DAPT for 1 year, 3.9% and 1.7%,

Table 1: Baseline and operative characteristics of patients discharged on DAPT or aspirin alone

| | DAPT | Aspirin (unmatched) | SMD | Aspirin (PS-matched) | SMD |
|--|--------------|---------------------|-------|----------------------|--------|
| <i>n</i> | 609 | 2308 | | 609 | |
| Age [mean (SD)] | 62.9 (9.4) | 62.9 (8.7) | 0.006 | 63.3 (8.4) | 0.052 |
| Female, <i>n</i> (%) | 73 (12.0) | 331 (14.3) | 0.070 | 78 (12.8) | 0.025 |
| BMI [mean (SD)] | 27.9 (4.4) | 28.3 (3.9) | 0.110 | 28.0 (4.0) | 0.027 |
| Creatinine [mean (SD)] | 101.2 (19.3) | 95.1 (21.3) | 0.301 | 101.2 (23.1) | 0.001 |
| DM, <i>n</i> (%) | 164 (26.9) | 531 (23.0) | 0.091 | 158 (25.9) | 0.022 |
| Smoking, <i>n</i> (%) | 86 (14.1) | 334 (14.5) | 0.010 | 75 (12.3) | 0.053 |
| COPD, <i>n</i> (%) | 47 (7.7) | 131 (5.7) | 0.082 | 42 (6.9) | 0.032 |
| PVD, <i>n</i> (%) | 49 (8.0) | 152 (6.6) | 0.056 | 50 (8.2) | 0.006 |
| Prior stroke, <i>n</i> (%) | 13 (2.1) | 68 (2.9) | 0.052 | 12 (2.0) | 0.012 |
| LVEF <0.50, <i>n</i> (%) | 136 (22.3) | 582 (25.2) | 0.068 | 141 (23.2) | 0.020 |
| LMD, <i>n</i> (%) | 112 (18.4) | 498 (21.6) | 0.080 | 134 (22.0) | 0.090 |
| MI within 1 year, <i>n</i> (%) | 149 (24.5) | 541 (23.4) | 0.024 | 156 (25.6) | 0.027 |
| PCI within 1 year, <i>n</i> (%) | 28 (4.6) | 265 (11.5) | 0.255 | 32 (5.3) | 0.030 |
| UA, <i>n</i> (%) | 252 (41.4) | 726 (31.5) | 0.207 | 236 (38.8) | 0.054 |
| Preoperative aspirin, <i>n</i> (%) | 534 (87.7) | 1989 (86.2) | 0.045 | 539 (88.5) | 0.025 |
| Preoperative clopidogrel, <i>n</i> (%) | 236 (38.8) | 462 (20.0) | 0.420 | 210 (34.5) | 0.089 |
| OPCAB, <i>n</i> (%) | 430 (70.6) | 760 (32.9) | 0.814 | 423 (69.5) | 0.025 |
| SVG, <i>n</i> (%) | 496 (81.4) | 1751 (75.9) | 0.136 | 491 (80.6) | 0.021 |
| <i>N</i> grafts [mean (SD)] | 3.3 (0.9) | 3.1 (0.8) | 0.224 | 3.3 (0.9) | 0.038 |
| Postoperative VKA, <i>n</i> (%) | 6 (1.0) | 87 (3.8) | 0.184 | 10 (1.6) | 0.058 |
| Postoperative BB, <i>n</i> (%) | 501 (82.3) | 1949 (84.4) | 0.059 | 501 (82.3) | <0.001 |
| Postoperative statins, <i>n</i> (%) | 581 (95.4) | 2118 (91.8) | 0.149 | 578 (94.9) | 0.023 |
| Postoperative ACEI/ARB, <i>n</i> (%) | 359 (58.9) | 1130 (49.0) | 0.201 | 348 (57.1) | 0.037 |

DAPT: dual antiplatelet therapy; SMD: standardized mean difference; PS: propensity score; BMI: body mass index; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; UA: unstable angina; LVEF: left ventricular ejection fraction; AF: atrial fibrillation; SVG: saphenous vein graft; OPCAB: off-pump coronary artery bypass; VKA: vitamin K antagonist; BB: beta blocker; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; LMD: left main disease.




Figure 2: Cumulative incidence with relative 95% confidence bands of MACCE (A) and of composite of cardiac death/MI and cerebrovascular accident (B) in patients discharged on DAPT or aspirin alone. MACCE: major cerebrovascular and cardiac events; MI: myocardial infarction; DAPT: dual antiplatelet therapy.

respectively, for those who switched to aspirin alone and 12.5% and 8.3%, respectively, for those who switched to clopidogrel alone. Our analysis was restricted to subjects who continued DAPT for 1 year (*n* = 188), while DAPT did not significantly influence MACCE (HR_{DR} 1.11, 95% CI 0.53–2.30; *P* = 0.78) or the composite of death, MI and CVA (HR_{DR} 0.62, 95% CI 0.22–1.69; *P* = 0.34).

Post hoc power calculation was based on a 2.0 percentage point reduction in MACCE (3.5% with DAPT vs 5.5% with aspirin

alone) accordingly to a pooled analysis recently published [3]. The power achieved was 90% (sample size 1218, 5% significance, 2 tails; Supplementary Material, Fig. S2).

Safety end-point

The rate of major bleeding was significantly higher in patients discharged on DAPT (14 of 609, 2.3%) when compared with

Table 2: Outcomes in matched patients discharged on DAPT or aspirin alone

| | DAPT | Aspirin (matched) | DAPT effect ^a |
|--|----------|-------------------|--------------------------|
| <i>n</i> | 609 | 609 | |
| MACCE, <i>n</i> (%) | 34 (5.6) | 34 (5.6) | 0.97 [0.59–1.59] |
| CV death/MI/CVA, <i>n</i> (%) | 21 (3.5) | 29 (4.8) | 0.71 [0.40–1.27] |
| Mortality, <i>n</i> (%) | 7 (1.2) | 9 (1.5) | 0.78 [0.29–2.1] |
| CV mortality, <i>n</i> (%) | 5 (0.8) | 8 (1.3) | 0.63 [0.21–1.91] |
| MI, <i>n</i> (%) | 11 (1.8) | 13 (2.1) | 0.84 [0.37–1.90] |
| CVA, <i>n</i> (%) | 9 (1.5) | 12 (2.0) | 0.75 [0.31–1.78] |
| Repeat revascularization, <i>n</i> (%) | 17 (2.7) | 9 (1.5) | 1.91 [0.85–4.33] |

^aEstimates obtained with Cox models stratified by PS-matched pairs and competing risk framework for MI, CVA and repeat revascularization.

DAPT: dual antiplatelet therapy; MACCE: major cardiac and cerebrovascular events; CV: cardiovascular; MI: myocardial infarction; CVA: cerebrovascular accident.

aspirin alone (25 of 2308, 1.1%; HR 2.14, 95% CI 1.11–4.11; $P=0.02$; Fig. 3), although this difference was no longer significant after PS matching (14, 2.3% vs 11, 1.8%; HR 1.30, 95% CI 0.58–2.8; $P=0.54$).

DISCUSSION

Based on the present *post hoc* analysis, there is no evidence that DAPT with clopidogrel can significantly reduce the rate of MACCE following surgery. However, in subjects admitted with UA and undergoing off-pump surgery, we found a non-significant trend towards a larger protective effect from DAPT. DAPT at discharge was associated with an increased risk of bleeding, but bleeding rates were particularly low in both groups.

Definitive guideline recommendations regarding the use of DAPT after CABG are currently lacking. Evidence for the use of DAPT following CABG is based mainly on a small proportion of patients in 3 landmark trials enrolling ACS patients [17–19]. Those trials were not adequately powered to address the role of DAPT in the post-CABG cohort. Another limitation is that they studied 3 different oral P₂Y₁₂ antagonists: clopidogrel, ticagrelor and prasugrel. Moreover, these results are based on post-randomization subsets from single randomized controlled trials in which DAPT was initiated prior to CABG. Therefore, the decision to undergo CABG is a post-randomization event occurring at variable times post-randomization. This decision can thus be influenced by randomized group resulting in potential baseline imbalances between intervention and control groups. On the other hand, available trials on DAPT enrolling CABG patients only present limited design and are largely underpowered to detect significant differences [20–25].

Patients were enrolled into ART from 2004 to 2007 and clopidogrel was the only P₂Y₁₂ antagonist used in this trial. Prasugrel and ticagrelor were approved for use in Europe in 2009 and 2010, respectively, and the question whether DAPT with newer P₂Y₁₂ antagonists is more effective remains to be determined. Of note, a recent meta-analysis [3] including 4 CABG subgroups ACS randomized controlled trials [17–20] ($n=3901$)




Figure 3: Cumulative incidence with relative 95% confidence bands of bleeding requiring hospitalization in patients discharged on dual antiplatelet therapy (DAPT) or aspirin alone.

and 5 post-elective CABG trials [21–25] ($n=986$) concluded that DAPT resumption with higher intensity P₂Y₁₂ antagonists (prasugrel or ticagrelor), but not clopidogrel, reduces all-cause mortality in ACS patients who have undergone CABG. In the ART, the vast majority of patients with prior MI within 1 year were discharged on aspirin alone in contrast with current recommendation to continue DAPT for 1 year following ACS regardless of the treatment adopted [4]. This might be partially explained by the fact that these recommendations have gained popularity after ART recruitment. We observed that subjects with UA showed a larger benefit from DAPT, although this result was not statistically significant. We also found that a non-significant trend towards better outcomes with DAPT in subjects undergoing off-pump surgery and those who received SVG, but these subgroup analyses were largely underpowered to detect significant difference.

It has been demonstrated that off-pump CABG is associated with hypercoagulability postoperatively [26], which can affect graft patency rate in particular with SVG. These patients may benefit more from DAPT than patients operated with conventional surgery although there is still paucity of evidence with conflicting results reported [24, 27].

Limitations

There are several limitations of the present study. Although a *post hoc* power calculation suggested that the present analysis was sufficiently powered to detect a difference in the primary endpoint (MACCE at 1 year) between the 2 groups. Subgroup analyses including subjects presenting with UA or receiving off-pump surgery or SVGs were largely underpowered. Despite PS matching, a residual imbalance cannot be excluded. In particular, we noticed that the rate of reintervention was higher in patients discharged on DAPT. This might partially be due to higher prevalence of risk factors for further coronary interventions in this group. Finally, only 31% of subjects initially prescribed on DAPT completed 1 year of treatment, and this aspect might have

underestimated the effect of DAPT. No data were available on DAPT duration in subjects who discontinued DAPT, and therefore, we were unable to discriminate the effect of short (3–6 months) versus long (1 year) DAPT. We performed a sensitivity analysis including only subjects who completed 1 year of DAPT and DAPT was confirmed to not be associated with better outcomes. We observed that the vast majority of bleeding occurred during the first 2 months from discharge, thus supporting the hypothesis that also short-term DAPT following CABG may increase the risk of bleeding.

CONCLUSION

In conclusion, based on these findings, there is no evidence of a significant benefit from DAPT with clopidogrel over aspirin alone following CABG. However, the present analysis was underpowered to investigate the effect of DAPT in high-risk subgroups, such as patients with ACS. Large prospective randomized controlled trials evaluating the use of DAPT post-CABG with higher intensity P₂Y₁₂ antagonists are urgently needed to provide more definitive guidance for clinicians.

SUPPLEMENTARY MATERIAL

Supplementary material is available at *EJCTS* online.

Conflict of interest: none declared.

REFERENCES

- [1] Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V *et al.* 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur J Cardiothorac Surg* 2014;46:517–92.
- [2] Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ *et al.* Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009;360:961–72.
- [3] Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M *et al.* Should dual antiplatelet therapy be used in patients following coronary artery surgery? A meta-analysis of randomized controlled trials. *BMC Surg* 2015;15:112.
- [4] Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA *et al.* 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Thorac Cardiovasc Surg* 2016;152:1243–75.
- [5] Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK *et al.* Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494–502.
- [6] Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S *et al.* Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007;357:2001–15.
- [7] Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C *et al.* Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009;361:1045–57.
- [8] Fitchett D, Eikelboom J, Fremes S, Mazer D, Singh S, Bittira B *et al.* Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. *Can J Cardiol* 2009;25:683–9.
- [9] Fitchett D, Mazer CD, Eikelboom J, Verma S. Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications. *Can J Cardiol* 2013;29:1042–7.
- [10] Krimly A, Yan RT, Yan AT, DeYoung JP, Gallo R, Steg G *et al.* Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes. *Can J Cardiol* 2011;27:711–5.
- [11] Rao RV, Goodman SG, Yan RT, Spencer FA, Fox KA, DeYoung JP *et al.* Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. *Am Heart J* 2009;157:642–50.
- [12] Taggart DP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM *et al.*; ART Investigators. Randomized trial to compare bilateral vs. single internal thoracic coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). *Eur Heart J* 2010;31:2470–81.
- [13] Taggart DP, Lees B, Gray A, Altman DG, Flather M, Channon K; ART Investigators. Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral versus single internal thoracic grafting in coronary revascularisation [ISRCTN46552265]. *Trials* 2006;7:7.
- [14] Rubin D. Multiple Imputation for Nonresponse in Surveys. New York: Wiley, 1987.
- [15] Austin PC. A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. *Multivariate Behav Res* 2011;46:119–51.
- [16] Cohen J. *Statistical Power Analysis for the Behavioral Sciences*, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates Publishers, 1988
- [17] Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ *et al.* Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. *J Am Coll Cardiol* 2012;60:388–96.
- [18] Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ *et al.* Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. *J Am Coll Cardiol* 2011;57:672–84.
- [19] Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ *et al.* Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. *Circulation* 2004;110:1202–8.
- [20] Saw J, Topol EJ, Steinhubl SR, Brennan D, Berger PB, Moliterno DJ *et al.* Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. *Am J Cardiol* 2004;94:623–5.
- [21] Gao G, Zheng Z, Pi Y, Lu B, Lu J, Hu S. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. *J Am Coll Cardiol* 2010;56:1639–43.
- [22] Sun JC, Teoh KH, Lamy A, Sheth T, Ellins ML, Jung H *et al.* Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the preoperative aspirin and postoperative antiplatelets in coronary artery bypass grafting study. *Am Heart J* 2010;160:1178–84.
- [23] Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S *et al.* Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the Clopidogrel after Surgery for Coronary Artery Disease (CASCADE) Trial. *Circulation* 2010;122:2680–7.
- [24] Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary artery bypaSS occlusion After off-pump procedures) randomised study. *Heart* 2012;98:1710–5.
- [25] Gasparovic H, Petricevic M, Kopjar T, Djuric Z, Svetina L, Biocina B. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. *Am J Cardiol* 2014;113:1660–7.
- [26] Nielsen AB, Bochsén L, Steinbruchel DA. Hypercoagulability and platelet inhibition after OPCAB: randomized trial with clopidogrel. *Scand Cardiovasc J* 2007;41:325–30.
- [27] Gurbuz AT, Zia AA, Vuran AC, Cui H, Aytac A. Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. *Eur J Cardiothorac Surg* 2006;29:190–5.